2015 All-America Research Team: Pharmaceuticals/Specialty, No. 3: Christopher Schott
Institutional Investor Research is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

2015 All-America Research Team: Pharmaceuticals/Specialty, No. 3: Christopher Schott

2015-10-tom-johnson-res-all-america-research-team-christopher-schott.jpg

Slipping from second place on this roster to the No. 3 position he held in 2013 is J.P. Morgan’s Christopher Schott.

< The 2015 All-America Research Team

2015-10-tom-johnson-res-all-america-research-team-christopher-schott.jpg

Christopher Schott

J.P. Morgan

First-place appearances: 0


Total appearances: 5


Analyst debut: 2011


Slipping from second place on this roster to the No. 3 position he held in 2013, J.P. Morgan’s Christopher Schott also rises one rung to claim the No. 2 spot on the Pharmaceuticals/Major list. The 38-year-old researcher is bullish on the U.S. specialty pharmaceuticals developers. “We see the group as well positioned, based on a combination of improving organic growth trends and a mergers-and-acquisitions cycle that we expect to continue into 2016 and beyond,” he explains. The industry “has moved up the value chain through M&A activity into higher-growth and ultimately high-multiple therapeutic areas, which we believe is not fully reflected in the sector’s valuation at 15 times 2016 [earnings per share].” Allergan — the surviving entity of May’s $70.5 billion merger between Ireland’s Actavis and Irvine, California’s Allergan — is his top pick in this space. “The management team has transformed the business through M&A over the past few years into a pure-play branded pharma company with healthy organic growth, a diversified product portfolio and limited patent risk,” he says. “After divesting its generics business, the company also has significant balance sheet capacity to pursue more transformative transactions, which we see as a catalyst for the stock.” His price objective of $400 implies a 35.5 percent upside to the shares’ value in mid-September.



Gift this article